PD-VALUE BV

Their core work

PD-VALUE BV is a Dutch computational pharmacology SME that builds mathematical models of how drugs behave in the human body — specifically quantitative systems pharmacology (QSP) models that simulate drug-target interactions, disease mechanisms, and patient variability. Their core value to a consortium is translating complex biological data into predictive models that guide which drug combinations work best for which patients. In MESI-STRAT they modeled breast cancer metabolic and signaling networks to stratify patients; in QSPainRelief they applied QSP to identify effective combinational treatments for chronic pain. The "PD" in their name almost certainly reflects their pharmacodynamics/PK-PD modeling expertise, which is a rare and specialized capability within EU drug research consortia.

What they specialise in

How they've shifted over time

PD-VALUE's H2020 trajectory shows a consistent computational modeling identity applied across shifting disease areas. Their early work (MESI-STRAT, 2018) was anchored in oncology — specifically modeling breast cancer metabolism and signaling networks to classify patients into treatment-relevant groups. By 2020, with QSPainRelief, the disease focus shifted entirely to chronic pain and combinational drug therapy, while the core methodology — QSP, in-silico modeling, personalized medicine — remained the throughline. This is a company deepening its modeling toolkit and applying it to new therapeutic problems, rather than changing direction.

PD-VALUE is moving toward quantitative systems pharmacology as a general-purpose platform for personalized treatment design, suggesting they would be a strong fit for any consortium seeking computational modeling of drug combinations or patient-specific dosing strategies across disease areas.

How they like to work

PD-VALUE has never led an H2020 project — they join as specialist partners, contributing their modeling expertise to consortia led by others. Across just two projects they have engaged 25 distinct partners in 9 countries, which indicates they are embedded in active, multi-partner European networks rather than working in isolation. This profile suggests they are a focused technical contributor: a consortium brings them in for their QSP modeling capability, not for project management or coordination.

Despite only two projects, PD-VALUE has built a notably broad network of 25 unique partners across 9 countries — averaging 12–13 partners per project, which is typical for RIA-scale Health pillar consortia. Their network is European in scope with no single dominant geographic cluster apparent from the data.

What sets them apart

PD-VALUE occupies a narrow but high-value niche: computational pharmacodynamic modeling as a service within drug research consortia. QSP expertise is scarce among SMEs — most QSP capacity sits inside large pharma or academic groups — which makes a dedicated QSP company like PD-VALUE a genuinely useful consortium asset. Their ability to operate across disease areas (oncology to pain) while maintaining the same modeling methodology means they bring transferable infrastructure, not just domain-specific knowledge.

Highlights from their portfolio

• QSPainRelief
  Their largest funded project (€298,375, running to 2025) and the clearest expression of their QSP identity — combining chronic pain pharmacology, drug combination optimization, and in-silico personalized treatment in a single RIA.
• MESI-STRAT
  Their entry into H2020 via a systems medicine breast cancer consortium, demonstrating early capacity to model complex metabolic-signaling networks for clinical patient stratification.